Celltrion Report Results of Truxima (biosimilar, rituximab) Based Regimen in P-II Study for R/R Aggressive B-cell Lymphoma #EHA25

Celltrion Reports Results of Remsima SC (biosimilar, infliximab) in a Clinical Study for Active Crohn’s Disease and Ulcerative Colitis #ECCO2020


  • Celltrion has presented the result of P-II study that showed that regimen of Truxima (375mg/m2) + lenalidomide (20mg, day 1-21, qd) + acalabrutinib (100mg, day 1-28, bid) (R2A) is well-tolerated and effective in relapsed/refractory aggressive B-cell lymphoma
  • In the 13 patients who underwent disease assessment following the R2A regimen, ORR (69%) and CR (31%), @6-mos. PFS (83%) and only one patient experienced disease progression after the initial objective response
  • Throughout the study, out of 22 patients, dose reduction was performed in 3 and 1 patients for lenalidomide and acalabrutinib respectively due to hematologic toxicities. The data indicate that the R2A regimen was well tolerated in Korean r/r BCL patients, with initial analysis in non-GCB DLBCL patients showing a promising response

Click here to read full press release/ article | Ref: Celltrion | Image: Celltrion